Benzinga’s Top Ratings Upgrades, Downgrades For September 13, 2022
Upgrades
See all analyst ratings upgrades.
Keybanc Initiates Coverage On Globant with Overweight Rating, Announces Price Target of $291
Keybanc analyst Thomas Blakey initiates coverage on Globant (NYSE:GLOB) with a Overweight rating and announces Price Target of $291.
Cowen & Co. Maintains Outperform on Globant, Raises Price Target to $248
Cowen & Co. analyst Bryan Bergin maintains Globant (NYSE:GLOB) with a Outperform and raises the price target from $220 to $248.
Globant: Q2 Earnings Insights
Globant (NYSE:GLOB) reported its Q2 earnings results on Thursday, August 18, 2022 at 04:15 PM.
Here's what investors need to know about the announcement.
Globant Shares Slide After Q2 Results, Clocks ~41% Revenue Growth
Globant SA (NYSE:GLOB) reported second-quarter revenue growth of 40.6% year-over-year to $429.3 million, beating the consensus of $425.55 million. Adjusted…
Earnings Scheduled For August 18, 2022
Companies Reporting Before The Bell
• Calliditas Therapeutics (NASDAQ:CALT) is expected to report quarterly loss at $1.00 per share on revenue of $7.50 million.